Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Flipo

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|June 29, 2012
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesisMarion Flipo, Nicolas Willand, Nathalie Lecat-Guillet, et al.
Npj Antimicrobials and Resistance|May 4, 2026
Molecular mechanism of transition-state inhibitors of bacterial antibiotic efflux pumpsClara Börnsen, Reinke T Müller, Anais Vieira Da Cruz, et al.
European Journal of Medicinal Chemistry|April 17, 2014
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysisJulie Charton, Marion Gauriot, Qing Guo, et al.
Journal of Medicinal Chemistry|May 14, 2014
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approachesBaptiste Villemagne, Marion Flipo, Nicolas Blondiaux, et al.
Journal of Medicinal Chemistry|March 23, 2011
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
Scientific Reports|May 12, 2018
Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticlesJoana Costa-Gouveia, Elisabetta Pancani, Samuel Jouny, et al.
Scientific Reports|July 16, 2017
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticlesJoana Costa-Gouveia, Elisabetta Pancani, Samuel Jouny, et al.
European Journal of Medicinal Chemistry|June 7, 2020
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screeningLéo Faïon, Kamel Djaout, Rosangela Frita, et al.
Journal of Medicinal Chemistry|November 22, 2011
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
EMBO Molecular Medicine|January 4, 2024
Pyridylpiperazine efflux pump inhibitor boosts in vivo antibiotic efficacy against K. pneumoniaeAnais Vieira Da Cruz, Juan-Carlos Jiménez-Castellanos, Clara Börnsen, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|June 29, 2012
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesisMarion Flipo, Nicolas Willand, Nathalie Lecat-Guillet, et al.
Npj Antimicrobials and Resistance|May 4, 2026
Molecular mechanism of transition-state inhibitors of bacterial antibiotic efflux pumpsClara Börnsen, Reinke T Müller, Anais Vieira Da Cruz, et al.
European Journal of Medicinal Chemistry|April 17, 2014
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysisJulie Charton, Marion Gauriot, Qing Guo, et al.
Journal of Medicinal Chemistry|May 14, 2014
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approachesBaptiste Villemagne, Marion Flipo, Nicolas Blondiaux, et al.
Journal of Medicinal Chemistry|March 23, 2011
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
Scientific Reports|May 12, 2018
Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticlesJoana Costa-Gouveia, Elisabetta Pancani, Samuel Jouny, et al.
Scientific Reports|July 16, 2017
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticlesJoana Costa-Gouveia, Elisabetta Pancani, Samuel Jouny, et al.
European Journal of Medicinal Chemistry|June 7, 2020
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screeningLéo Faïon, Kamel Djaout, Rosangela Frita, et al.
Journal of Medicinal Chemistry|November 22, 2011
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
EMBO Molecular Medicine|January 4, 2024
Pyridylpiperazine efflux pump inhibitor boosts in vivo antibiotic efficacy against K. pneumoniaeAnais Vieira Da Cruz, Juan-Carlos Jiménez-Castellanos, Clara Börnsen, et al.
Pageof 4